Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Romark Laboratories, L.C.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Phase 3

Completed

Conditions: Influenza

Interventions: Drug: Nitazoxanide
Drug: Oseltamivir
Drug: Placebo Oral Tablet
Drug: Placebo Oral Capsule

First Posted Date: 2012-06-01

Last Posted Date: 2018-03-29

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 1941

Registration Number: NCT01610245

Locations: 🇦🇺
Influence Study SIte, Nedlands, Western Australia, Australia
🇳🇿
Influence Study Site, Christchurch Central, Christchurch, New Zealand

Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children

Phase 2

Completed

Conditions: Rotavirus Infection
Viral Gastroenteritis Due to Rotavirus

Interventions: Drug: Nitazoxanide

First Posted Date: 2011-04-05

Last Posted Date: 2011-04-05

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 100

Registration Number: NCT01328925

Locations: 🇪🇬
Cairo University Children's Hospital, Cairo, Egypt

Nitazoxanide for the Treatment of Prolonged Diarrhea in Children

Phase 3

Completed

Conditions: Diarrhea

Interventions: Drug: Nitazoxanide

First Posted Date: 2011-03-30

Last Posted Date: 2011-03-30

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 100

Registration Number: NCT01326338

Locations: 🇵🇪
Regional Hospital of Cajamarca, Cajamarca, Peru

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Phase 2

Completed

Conditions: Influenza

Interventions: Drug: Placebo
Drug: Nitazoxanide

First Posted Date: 2010-10-25

Last Posted Date: 2023-10-12

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 624

Registration Number: NCT01227421

Locations: 🇺🇸
Health Sciences Research Center, Elmira, New York, United States

Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza

Phase 2

Terminated

Conditions: Influenza

Interventions: Drug: Placebo
Drug: Nitazoxanide

First Posted Date: 2010-01-26

Last Posted Date: 2018-04-05

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 79

Registration Number: NCT01056380

Locations: 🇺🇸
Health Sciences Research Center at Asthma and Allergy Associates, P.C., Elmira, New York, United States

4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Nitazoxanide
Biological: Peginterferon alfa-2a

First Posted Date: 2008-10-01

Last Posted Date: 2008-10-01

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 40

Registration Number: NCT00763568

Locations: 🇪🇬
Digestive Disease Center, Tanta, Egypt

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Placebo
Drug: Nitazoxanide
Biological: Peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2008-03-18

Last Posted Date: 2014-02-10

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 112

Registration Number: NCT00637923

Locations: 🇺🇸
Florida Center for Gastroenterology, Largo, Florida, United States
🇺🇸
New York Presbyterian-Weill Medical College of Cornell University, New York, New York, United States
🇺🇸
Palo Alto VA Healthcare System, Palo Alto, California, United States

and more 7 locations

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Placebo
Drug: Nitazoxanide
Biological: Peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2007-07-03

Last Posted Date: 2014-05-08

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 64

Registration Number: NCT00495391

Locations: 🇺🇸
VA Palo Alto Healthcare System, Palo Alto, California, United States
🇺🇸
McGuire VA Medical Center, Richmond, Virginia, United States
🇺🇸
Nashville Medical Research Institute, Nashville, Tennessee, United States

and more 7 locations

Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Nitazoxanide
Biological: Peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2007-01-12

Last Posted Date: 2008-09-25

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 121

Registration Number: NCT00421434

Locations: 🇪🇬
Department of Tropical Medicine & Infectious Diseases, Alexandria University, Alexandria, Egypt
🇪🇬
Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine, Tanta, Egypt

Study of Nitazoxanide in the Treatment of Chronic Hepatitis C

Phase 2

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2007-01-05

Last Posted Date: 2007-01-05

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 50

Registration Number: NCT00418639

Locations: 🇪🇬
Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine, Tanta, Egypt
🇪🇬
Cairo Liver & GIT Center, Cairo, Egypt
🇪🇬
Department of Tropical Medicine & Infectious Diseases, Alexandria University, Alexandria, Egypt

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy